Statins are widely prescribed to patients with lipid disorders or heart disease due to their proven cardioprotective efficacy. They inhibit hepatic cholesterol synthesis and increase hepatic cholesterol uptake. In addition, they have immune-modulating effects [2]. The latter may interfere with eczema or atopic eczema. Indeed, there are published reports of statin-induced dermatological complications, although the frequency of eczema has not been assessed previously [3,4].
In this retrospective analysis, data was derived from medical records of patients admitted to the University of Iowa hospitals and Clinics. Patients with heart disease who were taking a statin before 2012 were compared with patients with heart disease who had never been prescribed a statin. In both groups, the development of eczema/atopic dermatitis was assessed over a time period of 6 years. The data was stratified by various factors including gender, age, weight, BMI, alcohol consumption, and smoking status.
Patients taking statins had an incidence of eczema of 6.77% compared with 1.68% in those not taking statins (P<0.001). This translates into a >4-fold elevated relative risk of developing eczema in statin users. Male patients had a higher risk for eczema compared with female patients. There was also a higher incidence in eczema in non-Caucasians compared with Caucasians. Patients in the age group >60 years even had a 7 times higher relative risk to develop eczema compared with patients in this age group that did not take statins.
The study authors plan to elucidate this association further in a prospective trial to assess whether there are differences in the intake of different statins with respect to development of eczema.
- Cheung K, et al. Poster presented at 24th World Congress of Dermatology, 10-15 June 2019, Milan, Italy.
- Arnaud C, et al. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:127-34.
- Salna MP, et al. Case Rep Dermatol Med 2017; 3418204.
- Pedersen TR, et al. Arch Intern Med 1996;156:2085-92.
Posted on
Previous Article
« Will malignant melanoma become a curable disease? Next Article
Promising results of novel NMOSD treatments »
« Will malignant melanoma become a curable disease? Next Article
Promising results of novel NMOSD treatments »
Table of Contents: WCD 2019
Featured articles
Letter from the Editor
Insights into pathogenesis of AD define novel therapeutic targets
Treating Psoriasis in 2019
Choosing the right biologic in psoriasis
Registries – an important research tool in biologics
Atopic Dermatitis – What is New
Insights into pathogenesis of AD define novel therapeutic targets
Combinations are hot in AD treatment
Dermal Reactions to Systemic Drugs
Cutaneous adverse events due to EGFR inhibitors
Management strategies for drug-induced mucositis
Skin toxicity of immune checkpoint inhibitors
Lupus Erythematosus Today
New targets and biologics for cutaneous lupus erythematosus
Novel lupus classification will aid future research
Hidradenitis Suppurativa
Various guidelines with much overlap
Antibiotics in hidradenitis suppurativa
Biologicals beyond TNF blockade
Small Molecules – What to Expect
Novel treatment options for many dermatologic indications
Long awaited oral therapy for moderate-to-severe AD
Novel treatment options in alopecia areata and vitiligo
Optimising the Management of Keloids
Keloids: a faulty switch in wound healing?
What the future of keloid treatment could hold
Malignant Melanoma – Advances in Management
Will malignant melanoma become a curable disease?
Best of the Posters
Related Articles
July 31, 2023
PsA patients: highest risk of developing NAFLD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
